臨床研究等提出・公開システム

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease

Kuida Keisuke

Immunovant Sciences GmbH

1000 Park Forty Plaza, Suite 210, Durham, NC 27713, USA

clinicaltrials@immunovant.com

Clinical trial contact

ICON Clinical Research GK

Kyutaromachi 4-chome 1-3, Chuo-ku, Osaka city, Osaka 541-0056, Japan

+81-6-4560-2001

Japan-Chiken@iconplc.com

Pending

Jan. 14, 2027

Interventional

non-randomized controlled trial

open(masking not used)

no treatment control/standard of care control

treatment purpose

- Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
- Other, more specific inclusion criteria are defined in the protocol.

- Have permanently discontinued investigational medicinal product during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

Both

Graves' Disease

Group A: IMVT-1402 (Dose 1), administered subcutaneously (SC) once weekly (QW) for up to 52 weeks
Group B and Group C: No intervention

Percentage of Group A Participants who remain euthyroid, off antithyroid drugs (ATD), and off IMVT-1402 at Week 52

- Percentage of Group A Participants who are euthyroid and off ATD at Week 26
- Percentage of Group A Participants who are euthyroid and off ATD up to Week 52
- Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402 up to Week 52
- Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants up to Week 52
- Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 up to Week 52
- Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 at Week 52
- Time from Week 0 to the earliest date of confirmed relapse in Group B Participants up to Week 52
- Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 up to Week 52
- Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 at Week 52
- Time From Week 0 to the earliest date of confirmed relapse in Group C Participants up to Week 52
- Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for thyroid-stimulating hormone receptor antibody (TRAb) at Week 26
- Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb up to Week 52

+81-574-66-1100

Aug. 12, 2026

No

Australia/Belgium/Brazil/Bulgaria/Chile/Czech Republic/Georgia/Germany/Greece/Hungary/Israel/Italy/Latvia/Netherlands/New Zealand/Poland/Puerto Rico/South Korea/Spain/United Kingdom/United States